Nuage Therapeutics has successfully completed two projects funded through the Torres Quevedo programme (PTQ2021-011961 & PTQ2021-011994), strengthening its pioneering role in drug discovery.
These projects have supported Nuage’s development of a novel drug discovery approach, unlocking the draggability of intrinsically disordered proteins (IDPs) to deliver a new wave of transformative therapies. IDPs are a class of proteins long considered undraggable. This breakthrough opens the door to a new generation of transformative therapies.
This ground-breaking approach is currently being applied to target transcription factors that drive the growth of specific cancers, offering a revolutionary approach to treating certain tumour types.
Scientific, economic & strategic impact
The execution of these projects has had a transformative impact on Nuage’s trajectory as it has achieved several outstanding milestones:
- Attraction of international investment: Sofinnova Partners, one of Europe’s most prestigious capital venture firms in the biotech sector, has joined Nuage Tx, marking a significant milestone in the company’s growth.
- Participation in competitive R&D programs, both national and European: Nuage Tx has been awarded other highly competitive and prestigious grants, including the Proyectos de Colaboración Público-Privada from AEI (Agencia Estatal de Innovación, Spanish Agency for Innovation in English) and Eurostars 2025. These collaborations strengthen public-private partnerships and promote the internationalisation of R&D activities.
- Expansion of Nuage’s research pipeline: Nuage’s proprietary technology has been successfully tested against other IDPs, such as ASCL1, KLF5 and SOX2. These results demonstrate the platform’s potential to address a broader range of therapeutic needs.
Funding acknowledgement
The Torres Quevedo Programme is awarded by the Spanish State Research Agency (AEI) under the Spanish State Plan for Scientific, Technical and Innovation Research 2021-2023.
Ayuda PTQ2021-011961 y PTQ2021-011994 financiada por MICIU/AEI/10.13039/501100011033
(Ministerio de Ciencia, Innovación y Universidades / Agencia Estatal de Investigación)
